Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anne Marit de Groot"'
Autor:
Jinyan Liu, Dan H. Barouch, Mathieu Le Gars, Dirk Heerwegh, Makda S. Gebre, Katherine McMahan, Johan Van Hoof, Aiquan Chang, Jingyou Yu, Anne Marit de Groot, Macaya Douoguih, Kathryn E. Stephenson, Abishek Chandrashekar, Jerald C. Sadoff, Shivani A. Patel, Frank Struyf, Hanneke Schuitemaker
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported1–3. We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5
Autor:
Johan Van Hoof, Jinyan Liu, Macaya Douoguih, Jerald C. Sadoff, Frank Struyf, Makda S. Gebre, Jingyou Yu, Anne Marit de Groot, Mathieu Le Gars, Katherine McMahan, Abishek Chandrashekar, Shivani A. Patel, Aiquan Chang, Hanneke Schuitemaker, Dan H. Barouch, Kathryn E. Stephenson, Dirk Heerwegh
Publikováno v:
The New England Journal of Medicine
Interim immunogenicity and efficacy data for the Ad26.COV2.S vaccine for COVID-19 have recently been reported1-3. We describe here the 8-month durability of humoral and cellular immune responses in 20 individuals who received one or two doses of 5×1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e6ebc9b20b64e6752e0a9403099c3c
https://doi.org/10.1101/2021.07.05.21259918
https://doi.org/10.1101/2021.07.05.21259918
Autor:
Catherine Jacob-Dolan, Michael S. Seaman, Carolyn D. Alonso, Macaya Douoguih, Hanneke Schuitemaker, Ruvandhi R. Nathavitharana, Jinyan Liu, Lisa H. Tostanoski, Roger L. Shapiro, Jerald C. Sadoff, Kate Jaegle, Shivani A. Patel, Katherine E. Yanosick, Abishek Chandrashekar, Katherine McMahan, Jessica L Ansel, Chen S. Tan, Dan H. Barouch, Diane G. Kanjilal, Jingyou Yu, Morgana Souza, Douglas A. Lauffenburger, Anna Tyler, Anne Marit de Groot, Caitlin J. Guiney, Frank Struyf, Mathieu Le Gars, Connor Bradshaw, Kathryn E. Stephenson, Joseph P. Nkolola, Carla Truyers, Zhenfeng Li, Rebecca Zash, Boris Julg, Carolin Loos, Caroline Atyeo, Galit Alter, Johan Van Hoof, Dirk Heerwegh, Erica N. Borducchi, Makda S. Gebre, Lauren Peter, Tatenda Makoni, Ahmed Abdul Azim
Publikováno v:
JAMA
Importance Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c08377b16842fb53684d63f63c34e97
https://europepmc.org/articles/PMC7953339/
https://europepmc.org/articles/PMC7953339/
Autor:
Frank Struyf, Mathieu Le Gars, Ian M. Kaplan, Tochi Anioke, Catherine Jacob-Dolan, Erica N. Borducchi, Katherine McMahan, Macaya Douoguih, Florian Krammer, Sally Shin, Michelle A. Lifton, Abishek Chandrashekar, Joseph P. Nkolola, Lisa H. Tostanoski, David R. Martinez, Aiquan Chang, Jinyan Liu, Paul A. Fields, Kathryn E. Stephenson, Anne Marit de Groot, Jerald C. Sadoff, Harlan Robins, Hanneke Schuitemaker, Dan H. Barouch, Jingyou Yu, Ralph S. Baric, Dirk Heerwegh, Fatima Amanat, Caroline Atyeo, Galit Alter, Johan Van Hoof
Publikováno v:
Nature
The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c48aa07cacbb44fbd291d2931e461c0